Is it Too Late to Buy Gold?
Amid deep uncertainties about the future of the US economy,…
Sell
47
DRUG Quote, Financials, Valuation and Earnings
Last price:
$32.31
Seasonality move
:
-4.26%
Day range:
$31.64 - $33.47
52-week range:
$0.93 - $79.02
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.63x
Volume:
26.9K
Avg. volume:
33.4K
1-year change:
2825.45%
Market cap:
$226.7M
Revenue:
--
EPS (TTM):
-$0.18
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences
|
-- | -$0.32 | -- | -230.63% | $92.13 |
|
LLY
Eli Lilly and
|
$12.7B | $3.46 | 26.52% | 68.78% | $991.97 |
|
MRNA
Moderna
|
$115.3M | -$3.11 | -19.37% | -0.05% | $49.57 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.24 | 14.03% | -95.43% | $0.85 |
|
PFE
Pfizer
|
$14.1B | $0.68 | 1.91% | 5655.4% | $29.12 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences
|
$32.18 | $92.13 | $226.7M | -- | $0.00 | 0% | -- |
|
LLY
Eli Lilly and
|
$877.29 | $991.97 | $788B | 74.92x | $1.50 | 0.62% | 17.61x |
|
MRNA
Moderna
|
$27.46 | $49.57 | $10.6B | -- | $0.00 | 0% | 3.33x |
|
NBY
NovaBay Pharmaceuticals
|
$0.59 | $0.85 | $3.4M | -- | $0.00 | 0% | 0.16x |
|
PFE
Pfizer
|
$23.05 | $29.12 | $130.6B | 16.35x | $0.43 | 7.33% | 2.07x |
|
PTN
Palatin Technologies
|
$0.21 | -- | $5.5M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences
|
-- | -43.408 | -- | -- |
|
LLY
Eli Lilly and
|
70.33% | 0.800 | 5.05% | 0.59x |
|
MRNA
Moderna
|
-- | 0.004 | -- | 3.45x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.451 | 1.51% | 0.75x |
|
PFE
Pfizer
|
41.92% | 0.587 | 43.87% | 0.82x |
|
PTN
Palatin Technologies
|
-- | 0.220 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences
|
-- | -$1.2M | -- | -- | -- | -$1.1M |
|
LLY
Eli Lilly and
|
$11.1B | $5.8B | 25.09% | 80.24% | 38.89% | $726.6M |
|
MRNA
Moderna
|
$217M | -$1.2B | -29.09% | -29.09% | -123.22% | $303M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
PFE
Pfizer
|
$11.9B | $3.2B | 5.09% | 8.91% | 4.1% | $5.8B |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
Bright Minds Biosciences vs. Competitors
-
Which has Higher Returns DRUG or LLY?
Eli Lilly and has a net margin of -- compared to Bright Minds Biosciences's net margin of 32.59%. Bright Minds Biosciences's return on equity of -- beat Eli Lilly and's return on equity of 80.24%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences-- $0.01 -- LLYEli Lilly and82.24% $4.88 $47.9B -
What do Analysts Say About DRUG or LLY?
Bright Minds Biosciences has a consensus price target of $92.13, signalling upside risk potential of 188.47%. On the other hand Eli Lilly and has an analysts' consensus of $991.97 which suggests that it could grow by 13.07%. Given that Bright Minds Biosciences has higher upside potential than Eli Lilly and, analysts believe Bright Minds Biosciences is more attractive than Eli Lilly and.
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences2 0 0 LLYEli Lilly and16 3 1 -
Is DRUG or LLY More Risky?
Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.
-
Which is a Better Dividend Stock DRUG or LLY?
Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.62% to investors and pays a quarterly dividend of $1.50 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios DRUG or LLY?
Bright Minds Biosciences quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Bright Minds Biosciences's net income of $35.3K is lower than Eli Lilly and's net income of $4.4B. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 74.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus 17.61x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences-- -- -- $35.3K LLYEli Lilly and17.61x 74.92x $13.5B $4.4B
-
Which has Higher Returns DRUG or MRNA?
Moderna has a net margin of -- compared to Bright Minds Biosciences's net margin of -117.16%. Bright Minds Biosciences's return on equity of -- beat Moderna's return on equity of -29.09%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences-- $0.01 -- MRNAModerna22.7% -$2.91 $10.9B -
What do Analysts Say About DRUG or MRNA?
Bright Minds Biosciences has a consensus price target of $92.13, signalling upside risk potential of 188.47%. On the other hand Moderna has an analysts' consensus of $49.57 which suggests that it could grow by 80.52%. Given that Bright Minds Biosciences has higher upside potential than Moderna, analysts believe Bright Minds Biosciences is more attractive than Moderna.
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences2 0 0 MRNAModerna5 17 1 -
Is DRUG or MRNA More Risky?
Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.
-
Which is a Better Dividend Stock DRUG or MRNA?
Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or MRNA?
Bright Minds Biosciences quarterly revenues are --, which are smaller than Moderna quarterly revenues of $956M. Bright Minds Biosciences's net income of $35.3K is higher than Moderna's net income of -$1.1B. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus 3.33x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences-- -- -- $35.3K MRNAModerna3.33x -- $956M -$1.1B
-
Which has Higher Returns DRUG or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Bright Minds Biosciences's net margin of -49.65%. Bright Minds Biosciences's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences-- $0.01 -- NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About DRUG or NBY?
Bright Minds Biosciences has a consensus price target of $92.13, signalling upside risk potential of 188.47%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 45.3%. Given that Bright Minds Biosciences has higher upside potential than NovaBay Pharmaceuticals, analysts believe Bright Minds Biosciences is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences2 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is DRUG or NBY More Risky?
Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.
-
Which is a Better Dividend Stock DRUG or NBY?
Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or NBY?
Bright Minds Biosciences quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Bright Minds Biosciences's net income of $35.3K is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences-- -- -- $35.3K NBYNovaBay Pharmaceuticals0.16x -- $2.4M -$1.2M
-
Which has Higher Returns DRUG or PFE?
Pfizer has a net margin of -- compared to Bright Minds Biosciences's net margin of 2.31%. Bright Minds Biosciences's return on equity of -- beat Pfizer's return on equity of 8.91%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences-- $0.01 -- PFEPfizer66.74% $0.07 $152.1B -
What do Analysts Say About DRUG or PFE?
Bright Minds Biosciences has a consensus price target of $92.13, signalling upside risk potential of 188.47%. On the other hand Pfizer has an analysts' consensus of $29.12 which suggests that it could grow by 26.32%. Given that Bright Minds Biosciences has higher upside potential than Pfizer, analysts believe Bright Minds Biosciences is more attractive than Pfizer.
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences2 0 0 PFEPfizer6 14 1 -
Is DRUG or PFE More Risky?
Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.954%.
-
Which is a Better Dividend Stock DRUG or PFE?
Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.33% to investors and pays a quarterly dividend of $0.43 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or PFE?
Bright Minds Biosciences quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.8B. Bright Minds Biosciences's net income of $35.3K is lower than Pfizer's net income of $410M. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while Pfizer's PE ratio is 16.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus 2.07x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences-- -- -- $35.3K PFEPfizer2.07x 16.35x $17.8B $410M
-
Which has Higher Returns DRUG or PTN?
Palatin Technologies has a net margin of -- compared to Bright Minds Biosciences's net margin of --. Bright Minds Biosciences's return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences-- $0.01 -- PTNPalatin Technologies-- -- -- -
What do Analysts Say About DRUG or PTN?
Bright Minds Biosciences has a consensus price target of $92.13, signalling upside risk potential of 188.47%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 3233.33%. Given that Palatin Technologies has higher upside potential than Bright Minds Biosciences, analysts believe Palatin Technologies is more attractive than Bright Minds Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences2 0 0 PTNPalatin Technologies0 0 0 -
Is DRUG or PTN More Risky?
Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.
-
Which is a Better Dividend Stock DRUG or PTN?
Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or PTN?
Bright Minds Biosciences quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of --. Bright Minds Biosciences's net income of $35.3K is higher than Palatin Technologies's net income of --. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences-- -- -- $35.3K PTNPalatin Technologies-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NextEra Energy a Stock to Hold Forever?
NextEra Energy (NYSE:NEE) share price sold off hard in recent…
Why Did Bill Ackman Buy Alphabet Stock?
Bill Ackman has become famous in the investing world for…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Sell
39
RGC alert for Apr 29
Regencell Bioscience Holdings [RGC] is up 17.37% over the past day.
Buy
76
EXOD alert for Apr 29
Exodus Movement [EXOD] is down 7.23% over the past day.
Sell
48
SBGSY alert for Apr 29
Schneider Electric SE [SBGSY] is down 7.13% over the past day.
